Clinical Trial Update: A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 study of parsaclisib with bendamustine and rituximab for newly diagnosed mantle cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Parsaclisib (parsaclisib)
• Rituximab (rituximab)

Snippet

Sponsor: Incyte Corporation | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: WITHDRAWN